SCHEMBL6399748

SCHEMBL6399748

O=C(CN1CC(O)C1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.56
GRIN2B Q13224 13/20 0.54
GRIN1 Q05586 3/20 0.51
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
CES1 P23141 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
SIGMAR1 Q99720 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23805585 0.86 GRIN2B (0.63) ALDH1A1GRIN2BGRIN1
SCHEMBL6399006 0.86 ALDH1A1 (0.54) ALDH1A1GRIN2BKMT2ASLC6A4SLC6A3
SCHEMBL27406305 0.84 ALDH1A1 (0.59) ALDH1A1KDM4EMEN1HPGDKMT2A
SCHEMBL6403959 0.84 ALDH1A1 (0.54) ALDH1A1GRIN2BGRIN1KDM4EMEN1
SCHEMBL4875267 0.80 ALDH1A1 (0.79) ALDH1A1KDM4EMEN1CYP3A4MAPT
SCHEMBL7461492 0.80 KMT2A (0.63) ALDH1A1GRIN2BKDM4EMEN1MAPT
SCHEMBL18592898 0.78 GRIN2B (0.55) ALDH1A1GRIN2BGRIN1CYP3A4MAPT
SCHEMBL9381303 0.77 ALDH1A1 (0.69) ALDH1A1CYP3A4MAPTMAPK1KMT2A
SCHEMBL6399230 0.77 ALDH1A1 (0.59) ALDH1A1GRIN2BKDM4EMEN1CYP3A4
SCHEMBL16984989 0.76 ALDH1A1 (0.54) ALDH1A1GRIN2BCYP3A4MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 US disclosed
US-20050004092-A1 Penem derivatives and antimicrobial agent containing the same DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2005-01-06 US disclosed
EP-0757051-B1 PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME DAIICHI SUNTORY PHARMA CO LTD (JP) 2003-10-29 EP disclosed
EP-0774465-A1 Penem derivatives and antimicrobial agents containing the same SUNTORY LIMITED (JP) 1997-05-21 EP disclosed
EP-0757051-A1 PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME SUNTORY LIMITED (JP) 1997-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885GRIN2B 2868/4885GRIN1 2894/4885
US-20050004092-A1 Penem derivatives and antimicrobial agent containing the same MRPL21, MRPS2, MRPS28 ALDH1A1 1862/4885GRIN2B 1982/4885GRIN1 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.